



HHS Public Access

Author manuscript

Comput Toxicol. Author manuscript; available in PMC 2022 November 01.

Published in final edited form as:

Comput Toxicol. 2021 November ; 20: . doi:10.1016/j.comtox.2021.100186.

Developing Structure-Activity Relationships for *N*-Nitrosamine Activity

Kevin P. Cross^{*}, David J. Ponting[†]

^{*}Instem 1393 Dublin Road, Columbus, OH, USA

[†]Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, UK.

Abstract

The detection of *N*-nitrosodimethylamine (NDMA) in several marketed drugs led regulatory agencies to require that *N*-nitrosamine risk assessments be performed on all marketed medical products [EMA/351053/2019 rev 1 (2019)]. Regulation of *N*-nitrosamine impurity levels in pharmaceutical drug substances and products is described in the ICH M7(R1) guideline where they are referred to as “cohort-of-concern” compounds as several are potent rodent carcinogens [Kroes *et. al.* 2004]. EMA, U.S. FDA and other regulatory agencies have set provisional acceptable daily intake limits for *N*-nitrosamines calculated from rodent carcinogenicity TD₅₀ values for experimentally measured *N*-nitrosamines or the measured TD₅₀ values of close analogs. The class-specific limit can be adjusted based upon a structure activity relationship analysis (SAR) and comparison with analogs having established carcinogenicity data [EMA/369136/2020, (2020)]. To investigate whether improvements in SARs can more accurately predict *N*-nitrosamine carcinogenic potency, an ad hoc workgroup of 23 companies and universities was established with the goals of addressing several scientific and regulatory issues including: reporting and review of *N*-nitrosamine mutagenicity and carcinogenicity reaction mechanisms, collection and review of available, public relevant experimental data, development of structure-activity relationships consistent with mechanisms for prediction of *N*-nitrosamine carcinogenic potency categories, and improved methods for calculating acceptable intake limits for *N*-nitrosamines based upon mechanistic analogs. Here we describe this collaboration and review our progress to date towards

kevin.cross@instem.com .

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CrediT statement

David J. Ponting – Conceptualization, Methodology, Writing – Original Draft, Writing – Review and Editing, Data Curation, Visualization. Kevin P. Cross – Conceptualization, Methodology, Writing – Original Draft, Writing – Review and Editing, Data Curation.

Conflict of Interest

The authors are employed full-time by their respective companies which develop software for the prediction of chemical toxicity as listed as their affiliations and have performed this work as part of their research tasks in collaboration with each other and the informal working group discussed; no product, commercial, market or strategic information has been shared in discussion, nor has it influenced this work.

Declaration of interests

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kevin P. Cross reports financial support was provided by National Institute of Environmental Health Sciences of the National Institutes of Health. Kevin P. Cross reports a relationship with Instem that includes: employment, equity or stocks, and travel reimbursement.

development of mechanistically based structure-activity relationships. We propose improving risk assessment of *N*-nitrosamines by first establishing the dominant reaction mechanism prior to retrieving an appropriate set of close analogs for use in read-across exercises.

1. Introduction

Recently *N*-nitrosodimethylamine (NDMA) has been detected in several pharmaceutical marketed drugs. These events have led regulatory agencies to require that *N*-nitrosamines risk assessments be performed on all marketed medical products [1]. The need for these assessments is driven by the high carcinogenic potency of several *N*-nitrosamines in rodents, thus making these substances a significant regulatory concern [2]. Management of *N*-nitrosamine impurity levels in pharmaceutical drug substances and products has previously been guided by ICH M7 where they are referred to as “cohort-of-concern” (COC) compounds. Consequently, class-specific Acceptable Intake (AI) limits for *N*-nitrosamines are calculated from compound-specific carcinogenicity data by extrapolation of rodent TD₅₀ values. For *N*-nitrosamines without carcinogenicity data, regulatory agencies established provisional AI limits for several *N*-nitrosamine impurities based on structure activity relationships (SARs) with “close” analogs [3–6]. Currently, these regulatory limits are based on the AIs for the highly potent animal carcinogens NDMA and *N*-nitrosodiethylamine (NDEA). However, not all *N*-nitrosamines are highly potent (as measured by rodent TD₅₀ values), and their carcinogenic potency have been shown to span over 4 log units of TD₅₀ values [7,8]. Fortunately, the class-specific limit can be adjusted based upon a SAR analysis as part of a comparison with other similar *N*-nitrosamines that have established carcinogenicity data. The EMA Assessment Report on the subject [4] states, “It is therefore prudent to consider all *N*-nitrosamines containing an α -hydrogen that can be metabolically activated as potentially mutagenic and carcinogenic to humans, however with different potencies depending on nature of the functional group, specifics of metabolic activation and repair efficiency and capacity.”

To investigate whether improvements in SARs can more effectively predict *N*-nitrosamine carcinogenic potency, an ad hoc workgroup of 23 companies and universities was established to address several scientific and regulatory issues. These include:

1. reporting and review of *N*-nitrosamine mutagenicity and carcinogenicity reaction mechanisms,
2. collection and review of available, public, relevant experimental carcinogenicity and mutagenicity data,
3. development of SARs consistent with mechanisms for predicting *N*-nitrosamine carcinogenic potency categories, and
4. improved methods for calculating AI limits for *N*-nitrosamines based upon mechanistic analogs.

Herein we describe the progress made towards development of mechanistically based SARs, identifying the structural features that most affect carcinogenic potency. Specifically: 1) α -carbon substitution, and 2) electron-withdrawing groups on nitrosamine carcinogenicity

potency and mutagenicity prevalence. The features that impact an SAR of a complex biological process such as carcinogenesis may include a number of different events. The key events driving DNA mutagenicity from dialkyl *N*-nitrosamines include: metabolic activation, DNA alkylation and the repair of potential DNA adducts. While these events could potentially result in different SARs, the metabolic activation mechanism is understood [9,10] to be of principal concern for the overall SAR – since if a nitrosamine is not metabolically activated, the SAR for binding and repair is of less relevance. A three-stage consideration of the SAR, however, may be necessary in some cases to fully explain the potency of some dialkyl *N*-nitrosamines.

1.1 Metabolic activation mechanisms for dialkyl *N*-nitrosamine mutagenicity

Given the significance of the metabolic activation in understanding the overall SAR, current understanding is briefly summarized here. It has been reported[9,10] that several different competing metabolism mechanisms primarily drive the potency for dialkyl *N*-nitrosamines, with uninhibited metabolic activation via α -carbon hydroxylation producing the most potent carcinogens. The mechanism for the highest potency dialkyl *N*-nitrosamines (i.e., those with the lowest TD50 values available in the carcinogenicity database) is that of α -carbon hydroxylation via metabolic activation, as indicated in figure 1 [9–12]. It has been reported that multiple stages of this, including that marked as heterolysis, may be catalysed by the same P450 enzyme without relaxation of conformation – resulting in the loss of the R1-bearing side as a carboxylic acid as opposed to an aldehyde[13,14]; however, in other cases such as nitrosomorpholine, the reactive aldehyde intermediate is significant and trapped intramolecularly[15].

For small dialkyl nitrosamines, the predominant enzyme responsible for the activation of the nitrosamine to intermediate **I** is reported to be Cytochrome P450 2E1 (Cyp 2E1) [12]; however, the active site of this specific isoform is particularly small, and a number of other P450 isoforms may become involved for larger nitrosamines. Examples of particular relevance are: Cyp 2A6 – also relevant for small nitrosamines [11,12,14]; Cyp 2C9 – substrates with an anionic site, and of specific orientation requirements [16,17]; 2C19 – Zwitterionic compounds [17]; 2D6 – cationic site [17] and Cyp 3A4 – which is able to metabolise particularly large substrates [17].

Many factors can contribute to nitrosamine carcinogenicity potency, including:

- a. the relevant P450 enzymes summarised above and their levels in various target organs – which can vary between species and between individuals [11]
- b. compound solubility, size, and shape[18],
- c. potential phase II conjugation (such as carboxylic acid-containing compounds being substrates for e.g., glucuronidation directly),
- d. the stability of intermediates such as carbocation and diazonium ion stability,
- e. DNA adduct profiles and the level of mutagenic adducts, and
- f. DNA repair mechanisms and their capacity levels.

There can also be competing metabolic activation mechanisms, such as β -carbon [9,19], γ -carbon [19], and ω -carbon hydroxylation [9,19], as well as mechanisms such as denitrosation[20], and trans-nitrosation [21], which may be either metabolically mediated (in the case of denitrosation, potentially via the same radical intermediate as α -hydroxylation[22]) or not.

This investigation will focus on identifying the structural characteristics that affect dialkyl *N*-nitrosamines potency and how they may be used to determine the relative potency of these different nitrosamines.

2. Material and Methods

2.1 Dataset curation

Data was extracted from historic rodent carcinogenicity and mutagenicity sources and curated according to the respective standard protocols by a number of separate data-gathering exercises – Lhasa Limited’s Vitic (2020) [7,23], Instem’s Leadscope Genetox and Carcinogenicity Databases (2020) [24] and the now-retired Carcinogenicity Potency Database (CPDB) [25,26] available as the Lhasa Carcinogenicity Database [LCDB, carcdb.lhasalimited.org]. Data extraction from CPDB/LCDB was performed in-house at Lhasa Limited from the source data, extracting all data for structures that match NN(III)=O and filtering via substructure patterns in Knime (www.rdkit.org, as implemented in KNIME version 4.1.0, www.knime.org) to remove those structures that match the non-dialkyl compounds shown in figure 2. These compound classes, such as nitrosoureas, nitrosamides and similar compounds are known to exert mutagenic and carcinogenic potential via different mechanisms and have therefore been excluded from this analysis. A similar approach was taken to the Vitic data, using the same substructural features, and extracting all data from the ‘Carcinogenicity’ and ‘Genetic Toxicology – in Vitro’ tables; data from the latter was then filtered to Ames test or synonyms only. Data extraction from the Leadscope Genetox and Carcinogenicity Databases was similarly performed in-house at Instem from the source data, extracting all data for structures that match NN(III)=O and filtering using Leadscope substructure search functionality. The latter was filtered to include compounds containing Ames test data and carcinogenicity calls. Data from these three sources were curated together manually, creating a combined dataset with consensus calls for carcinogenicity and Ames test data.

2.2 Choice of structural features

Exploratory investigations were performed using a subjective analysis of TD₅₀ [27,28] potency data from the LCDB previously described[7,29] using substructure patterns for features previously identified [9,10] Several distinct substructural categories were identified and two were chosen to investigate in more depth:

1. the degree of α -branching of the nitrosamine (Figure 3)
2. the presence or absence of electron-withdrawing groups (Figure 4)

2.3 Data analysis

The structural categories described in figures 1, 3 and 4 were manually encoded into substructure patterns using the SMARTS notation [31], and pattern-matching was performed against the dataset described using RDKit (www.rdkit.org, as implemented in KNIME version 4.1.0, www.knime.org). Data analysis and visualisation was performed in python (www.python.org, version 3.7.6).

The two alkyl substituents of the molecule were considered both separately and in combination (i.e., with R1 in figures 1, 3 and 4 either kept as “C except C=O, C=N” or explicitly defined, respectively), and thus an exponentially large number of potential feature combinations exist. Many of these, however, have no examples in the dataset and are thus unable to be considered.

3. Results

The curation of carcinogenicity and Ames study data described resulted in a consensus dataset of 362 dialkyl *N*-nitrosamines. Of these, 208 have carcinogenicity data (including TD₅₀[27,28] values for 74 of these) and 281 have Ames study data. Analysis of the concordance between these endpoints has been performed elsewhere [Trejo-Martin et al, manuscript in preparation, [7,29]], and is reported to be excellent. The reasons for the lack of a TD₅₀ for many of the carcinogenicity records include principally that for 120 compounds a study exists in the Lhasa and/or Instem dataset that was not incorporated in the CPDB and 14 compounds for which at least one record exists in the CPDB, but no TD₅₀ was able to be determined by Gold *et al* (typically due to a negative result in the study).

3.1 Categorizing nitrosamine potency by structural features

The analysis focused on extracting and developing chemistry-based knowledge by uncovering trends in the chemical feature-activity space that are represented in the database. The objective is ultimately to encode the expert, intellectual knowledge into alerts for identification of carcinogenicity potency categories for compounds (based on rodent TD₅₀ values). As it is not the intent to develop statistical (Q)SAR models using these features, the number of observations is not as important as is the relevance of chemical features to known organic chemistry reactivity and functional group properties.

A closer examination of the many structural features that can affect dialkyl *N*-nitrosamines is presented in figure 6. This figure shows a summary of all the structural features investigated thus far. Many potential features had few observations and the presence of multiple substituents per compound can sometimes complicate the analysis when carbon hydroxylation can potentially occur on either substituent. Since the relative amount of 2-year rodent carcinogenicity bioassay data is low and there is little expectation of new data being generated, the potency trends established from analysing the carcinogenicity data were corroborated by comparing the Ames mutagenicity data for prevalence of positive and negative results with carcinogenicity potency trends. This comparison is supported by the high sensitivity of Ames study results in predicting rodent carcinogenicity [7,29] and the fact

that nitrosamine mutagenicity is observed to occur via alkylation at specific DNA base sites (e.g., O⁶-guanine[32]) in a mutagenic mechanism [9,10].

Based upon these considerations, the current investigation chose to initially analyse and report the steric effects of α -carbon substitution and electronic effects of β -carbon electron-withdrawing groups on nitrosamine carcinogenicity potency and mutagenicity prevalence.

3.2 The effects of degree of α -carbon substitution on nitrosamine carcinogenicity potency and mutagenicity prevalence

The first category investigated is the degree of α -branching of the nitrosamine, which has historically been reported [9,10] to have a significant impact on potency – indeed, dialkyl nitrosamines lacking any α -carbon hydrogens are indicated by the European Medicines Agency (EMA) to be of lower concern [4]. Figure 3 gives the structural definitions used to identify these classes.

While much of the literature on nitrosamines has concentrated on experiments measuring NDMA and NDEA potency, Figure 6 shows that these small nitrosamines constitute a very potent but limited nitrosamine set with a tight TD₅₀ value range. Larger nitrosamines, such as those for drug-like compounds, have TD₅₀ ranges spanning 4 orders of magnitude and containing examples of compounds with much lower potency and significant potency differences between structural classes. When comparing the “Only Et/Me” plot with the “Has Et/Me” plot it can be seen that increasing the size of a nitrosamine substantially increases the range of possible TD₅₀ potency values. The reasons for this discrepancy may have a number of origins.

The “Has acyclic α -CH₂ (not Et/Me)” and “Has cyclic α -CH₂” plots illustrate that potency generally decreases for nitrosamines with increasing chain length and ring size (though there are some notable exceptions to this trend). Lastly, the “No α -CH₂” plot is of particular interest. There are two compounds in this category with TD₅₀ values; firstly, 2,6-dimethyl-N,N'-dinitrosopiperazine contains both a substituted and unsubstituted nitrosamine, and thus matches the substructure pattern for having two isopropyl groups. However, it also has a reactive, unsubstituted nitrosamine that is the probable source of mutagenesis and carcinogenesis – and hence this compound is worthy of inclusion in the cohort-of-concern and matches both the “No α -CH₂” (at one nitrosamine substitution site) and “Cyclic α -CH₂” (at the other). Secondly, nitrosodiphenylamine, which is the weakest carcinogen in the nitrosamine dataset for which a TD₅₀ was calculated (167 mg kg⁻¹ day⁻¹). When this is combined with the observations from figure 7 below, potency and also prevalence are significantly reduced. Therefore, it can be argued that nitrosamine groups with zero or one α -carbon hydrogen lack carcinogenic potency to such an extent that, even when positive, their TD₅₀ values would no longer fall within the level for cohort-of-concern described in the ICH M7 guideline. This assumes, of course, that they are the only alerting substructural feature present.

Figure 7 continues this analysis by more precisely illustrating the effects of α -carbon substitution and steric bulk on nitrosamine carcinogenicity and mutagenicity prevalence. Functionally, the “no α -CH₂” category of the plot in figure 6 contains compounds with

two of any one of the following – isopropyl, *tert*-butyl and/or aryl groups – as their substituents; note there is no data for the compounds with mixed arrangements such as isopropyl and aryl. These effects arising from the substituents have previously been reported [9,10], but are re-examined and confirmed here in light of additional data and decades of scientific advances. The top row histograms include data from binary (positive/negative) carcinogenicity data in addition to compounds having TD₅₀ values. The “Two CH₂ groups” histogram illustrates the strong prevalence of positive carcinogenicity for compounds having 2 or 3 hydrogens on at least one of the α -carbon positions. The “CH₂ with iPr” histogram illustrates that substitution of an isopropyl group (or longer) at one of the α -carbon positions reduces the prevalence of positive carcinogenicity compounds while “Two iPr groups” illustrates that isopropyl (or longer) substitutions at both positions reduces positive prevalence even more so. There is one exception to this trend without clear reason: *N*-nitrosodiisopropylamine (NDIPA) (Trejo-Martin *et al*, in preparation). The other compounds with positive results in this category are explainable. Firstly, 2,6-dimethyl-*N,N'*-dinitrosopiperazine (figure 8) as discussed with reference to figure 7. Secondly, methyl 1-methyl-6-nitro-2-nitroso-1,3,4,9-tetrahydropyrido(3,4)-indole-3-carboxylate (figure 8) is carcinogenicity positive but contains a nitro group on a polycyclic aromatic, and these are known structural alerts for genotoxicity independent of the hindered nitrosamine. When a *tert*-butyl group substitution is present, the “CH₂ with tBu” histogram illustrates that a lack of α -carbon hydrogens on just one side of the nitrosamine can negate genotoxicity. This occurs despite the presence of methyl/ethyl groups on the other side which can be assumed to be metabolically labile, and therefore may be due to a lack of ability for the cation to alkylate nucleic acids [33]; this shows the importance of the three-stage SAR consideration discussed in section 1. If two *tert*-butyl groups are present there are of course no α -hydrogens, and compounds with this feature are likewise carcinogenicity negative.

Lastly, the “CH₂ with aryl” histogram illustrates that the presence of one aryl substitution may also reduce carcinogenicity prevalence. The specific effect likely depends not only the presence of an aryl ring (versus a non-aryl ring – which with the open patterns used here appears as ‘isopropyl’-like) but on substitutions at the ortho, meta, and para positions on that ring (such as the differing results between 2-,3- (and 4-) (*N*-nitroso-*N*-methylamino)pyridine (figure 8, center), and the nature of the substituting groups. For the nitrosomethylaminopyridine series, the nature of the pyridinyl cation or diazopyridine may explain the different toxicity profile. An organic chemists’ understanding would normally be that the 2- and 4- derivatives would be comparable and the 3- different due to the delocalisation patterns within the aromatic ring; however, this is not the case. Rather, the 2-derivative is different, which may be due to the proximity of the pyridinyl nitrogen and its lone pair (both as a potential base and as a lack of steric hindrance when compared to a CH group) to the cation/diazonium site[34]. These effects in this and similar systems will be the focus of future investigations. While the aryl group itself provides no α -carbon hydrogens for metabolic activation via the standard mechanism, it may well be able to alkylate DNA. The difference in carcinogenicity effects, between the similarly hydrogen-free *tert*-butyl group (which seems to eliminate genotoxic potential) and the aryl group also bears further investigation.

The bottom row of graphs in figure 7 provides an analysis of the same patterns of substitution on a larger set of Ames study data. These histograms compare favorably with the carcinogenicity histograms, reinforcing the same resulting trends.

Again, this analysis approach is focused on extracting and developing chemistry-based knowledge by uncovering trends in the chemical feature-activity space that are represented in the database. Even though the number of observations is limited, finding associations of these chemical features with known organic chemistry reactivity and functional group properties provides a theoretical justification for these effects and allows us to use these chemical properties in the future to predict the carcinogenicity of new compounds having such groups.

In summary both the extent of α -carbon substitution and steric bulk can significantly reduce or even potentially eliminate carcinogenicity.

3.3 The effects of β -carbon electron withdrawing groups on nitrosamine potency and mutagenicity prevalence

The second category investigated is the presence or absence of β -electron-withdrawing groups since several compounds with these features have reported to be of lower potency or non-carcinogenic. Early investigations [29] showed that this rule is not universal, however, a number of compounds with the 2-oxo-propyl functionality are still potent. Such potency may be due either to the acidity of the enol protons in this case, or due to a reduction in this electron-withdrawing potential compared to other groups (such as trifluoroethyl). As a result, the electron-withdrawing groups were divided into strong and weak categories (after Remya and Suresh [30]), as shown in figure 4. These categories represent a commonly-observed subset of the possible electron-withdrawing groups, using an approximate energy difference cut-off (ΔV_e) of 10 kcal mol⁻¹. This is only an approximate cut-off value due to the need to group the specific structures modelled by Remya and Suresh according to the substructure patterns [30]. However, it covers all electron-withdrawing groups observed in the dataset. One obvious exception from the carbonyl/carboxyl category that is represented in the dataset are the carboxylic acids. These are expected to be deprotonated *in vivo* – either in isolation or forming a Zwitterion with the amine N of the nitrosamine – and thus not electron-withdrawing. An example of this is *N*-nitrosoproline whose negative charge at physiological pH, likely prevents it from entering cells and thus evading the cytochrome P450 metabolism [35,36].

The carcinogenic potencies of nitrosamines containing strong, weak, and no β -carbon electron withdrawing groups are illustrating in figure 9. While there were limited examples of strong withdrawing groups in the carcinogenicity potency data set, its presence was associated with a reduction in carcinogenic potency while weak withdrawing groups showed less effect.

Figure 10 more clearly illustrates the effect of β -carbon electron withdrawing groups on nitrosamine mutagenicity prevalence as it considers binary carcinogenicity data in addition to only positive nitrosamines having TD₅₀ values. In this figure we see that a single weak electron withdrawing group appears to have a limited effect on carcinogenicity as

compared to the general trend for all compounds. The presence of two weak electron withdrawing groups (as in nitroso-bis(2-oxopropyl)amine, figure 11) appears to have little to no effect on mutagenicity though possibly some minor effect in reducing carcinogenicity albeit there is little data present. The effect of a single strong electron withdrawing group negating carcinogenic potential is more clearly seen. The presence of two electron withdrawing groups is seen to negate carcinogenic potential – compare the tri- and hexa-fluoro compounds in figure 11. The presence of β -carbon electron withdrawing groups is associated with a reduction in the prevalence of carcinogenicity potency with most effect resulting from strong and multiple groups.

4. Discussion

4.1 NDMA and NDEA activity and their relevance to other *N*-nitrosamine potencies

NDMA and NDEA have been extensively studied both experimentally and mechanistically [27,37–39]. The potencies of these compounds have been used as references for establishing the regulatory limits for many nitrosamines [3–6]. However, these are very small, volatile compounds containing no functional groups beyond the nitroso moiety. Consequently, unlike larger nitrosamines such as those in drug impurities, they are characterized by specific physico-chemical properties and ADME (absorption, distribution, metabolism, and elimination) profile, and they would not exhibit steric hinderance or electronic effects limiting their reactivity and subsequent carcinogenicity potency.

One path for carcinogenicity of many nitrosamines is believed to be via mutagenicity as a result of DNA adduct formation albeit a quantitative relationship has not been determined nor has the method of action been yet proven [19,40]. Consequently, DNA adduct formation is used as a biomarker but is not a regulatory endpoint. The principal reaction mechanism for NDMA and NDEA is the hydroxylation of the α -carbon which is metabolized via CYP450 2E1 [9]. After metabolic activation, intermediate **I** (figure 1) is formed, potentially stabilised by an intramolecular hydrogen bond (rotation around the nitrosamine group is restricted). Thus the molecule may or may not be in the correct configuration to form this intermediate [41]. This is followed by heterolysis and subsequent diazonium ion formation before ultimately alkylating DNA [19,41].

However, there are several characteristics of this metabolic activation mechanism that are key in determining the extent of DNA adduct formation. These vary significantly across different subclasses of nitrosamines consequently affecting the relative potency of subclasses which may make the use of default potencies (e.g. rodent TD₅₀ values) of NDMA and NDEA not always the most appropriate. These characteristics include:

1. This mechanism depends on the availability of CYP enzymes for the extent of reactivity and thus potency. The 2E1 enzyme levels vary by species (rat vs hamster vs human) as well as organ [42–44]. Variation by species leads to different experimental results for both *in vivo* and *in vitro* studies (for example the use of hamster vs rat S9 in Ames salmonella tests). Those species with higher 2E1 liver enzymes may be a more sensitive tester species. This also complicates assessment of human relevancy due to relative enzyme

levels. For large nitrosamines, enzymes other than 2E1 (such as 2C9, 2A6 and ultimately 3A4) become responsible for hydroxylation since the active site of 2E1 is proportionally very small and larger nitrosamines do not fit [16,17]. Consequently, the rate and SAR of hydroxylation of these compounds can vary significantly from that for NDMA and NDEA. Different relevant enzyme levels in different organs affects the susceptibility of organs to tumor formation. Whilst relevant liver enzyme levels are the highest amongst target organs, metabolism outside of the liver (such as bladder, stomach, and esophagus) may also occur and subsequently results in tumor formation[45].

2. This mechanism depends on the availability of the hydrogen on the α -carbon for metabolic activation to occur. Substitution at the α -carbon on one or both sides of the nitroso group affects reactivity. If there are no α -carbon hydrogens available this metabolic mechanism is completely inhibited (competing mutagenicity mechanisms may still theoretically occur, but in practice the blocking of this mechanism removes the need to consider the compound as part of the cohort-of-concern [4]). As fewer α -carbon hydrogens are present (with 6 being the maximum in NDMA) more inhibition of the mechanism occurs.
3. If the substitution patterns are different on each side of the nitroso group, two different DNA adducts may occur depending on which α -carbon hydrogen is predominantly metabolized. The proportion of different resulting adducts depends on the relative ease of hydroxylation of each side group. NDMA and NDEA have symmetrical substituents and thus produce only a single (small) adduct for alkylation (methyl or ethyl respectively) with no competition. In comparison, nitrosomethylethylamine (NMEA) can cause both DNA methylation and ethylation, and it has been observed that blocking the ethyl site, as in nitrosomethylneopentylamine (NMNA), results in only methylation with tumors specific to a particular organ (the esophagus) [46]. Additional organotrophic carcinogenic effects have been reported between symmetrical and asymmetrical nitrosamines[18].
4. Substitution affects steric access to the α -carbon. As steric bulk, such as isopropyl groups are added as part of the nitroso substituents, α -carbon hydroxylation can become partially or totally inhibited due to steric hinderance. Consequently, not all nitrosamines will have the same unfettered ability to undergo α -carbon hydroxylation as NDMA or NDEA.
5. The electrostatic effects of different substituents will alter reactivity. Differences in electrophilicity due to the presence of, for example, electron-withdrawing groups, on nitroso substituents can make the energetics of the α -hydroxylation mechanism less favorable. NDMA and NDEA display no such effects.
6. Substitution affects the potential formation and stability of the hydrogen bonding intermediate **I**. The formation of this intermediate ring depends on the correct structural orientation for hydrogen-bonding to occur as the hydroxyl hydrogen is hydrogen-bonded to the nitroso oxygen [S. Yu, et. al., manuscript in preparation].

Large and bulky substituents will affect energetics which are favorable to ring formation in NDMA and NDEA. The presence of additional functionality on nitroso substituents (such as β or γ hydroxyl groups) can also interfere not only with ring formation but may also lead to the formation of additional hydrogen-bonded rings between the two sides of the nitrosamine which can be energetically more favorable than the intermediate required for diazonium ion formation.

7. Other reaction mechanisms may well compete with α -carbon hydroxylation [9]. As NDMA and NDEA are relatively featureless, there is little competition from other known reaction mechanisms. However, there can be several different reaction mechanisms that compete with α -carbon hydroxylation for other *N*-nitrosamines including hydroxylation at other (β , γ , and omega) carbon sites [9,19] and denitrosation [20]. The presence of a different dominate reaction mechanism reduces the potency of a particular *N*-nitrosamine subclass relative to NDMA and NDEA.
8. The presence of hydroxyl groups on *N*-nitrosamines substantially affects the stability and solubility of *N*-nitrosamines[47]. α -hydroxylated dialkyl-*N*-Nitrosamines only have a half-life of up to 10 seconds under physiologic conditions before they spontaneously decompose to an aldehyde or (ultimately) diazonium hydroxide which reacts predominantly with water and is then cleared from the system (but also reacts with DNA) [48]. Consequently, the site in the body where α -carbon hydroxylation occurs can influence the organ tumor site. In theory, hydroxylated *N*-nitrosamines may be less potent carcinogens due to their solubility. However, when considering hydroxylation at these additional positions, other enzymatic reaction mechanisms such as oxidation to aldehydes and carboxylic acids via alcohol dehydrogenase may result in their conversion to potent direct-acting carcinogens [49]. Hence the presence of alcohol, aldehyde, and carboxylic acid functionality complicates potency determination via several alternative pathways. These effects are not seen in NDMA or NDEA.
9. The effectiveness of *in vivo* detoxification mechanisms is dependent on nitroso substituents. The detoxification pathways for drugs occurs via second phase metabolism in the liver where conjugation occurs resulting in a stable, soluble compound more easily cleared from the body [50,51]. There are several types of conjugates relevant to nitrosamines that can be formed, including glucuronides, sulfonates, and glutathione conjugates [19]. The prevalence for conjugate formation (and which type of conjugate) depends on the chemical functionality present in the nitroso substituents. Denitrosation, resulting in the secondary amine formation is yet another “detoxification” mechanism resulting in carcinogens that are less potent than those from α -carbon hydroxylation [20]. Detoxification through conjugate formation is not observed with NDMA or NDEA though denitrosation is observed [52].
10. Labile functional groups such as thiol or ether moieties affect reactivity and potency. Such groups in nitroso substituents will change the reactivity

of an *N*-nitrosamine, resulting in conjugate formation or direct cleavage of the compound, for example cleavage at the thiol or ether functional group. Long chain substituents may be subject to pre-metabolic oxidation clipping of the carbon chain resulting in more potent carcinogenicity than expected [9,53,54]. The featureless NDMA and NDEA structures do not possess these characteristics.

11. DNA repair mechanisms are different for adducts larger than methyl and ethyl alkylation and involve repair of more than just DNA adducts via alkyltransferases [55–57]. The focus on NDMA and NDEA DNA mutations considers only the DNA repair mechanisms for methylation and ethylation, (specifically methyl and ethyl transferases), while repair of bulky adduct formation involves other alkyltransferases as well as base and nucleotide excision repair mechanisms.
12. NDEA and NDMA are low molecular weight *N*-nitrosamines. When a read-across exercise is performed with these as analogs and a weight-based AI limit (as opposed to molarity) is extrapolated for a larger compound, the derived limit permits even fewer molecules of the larger compound. Hence a molarity-based limit may provide a more relevant comparison.

As demonstrated here, the mechanism resulting in NDMA and NDEA potency may not translate well when assessing other, more complicated *N*-nitrosamines. Their lack of substituents beyond methyl and ethyl groups in these small nitrosamines results in a very limited set of parameters affecting their potency that may be present in all the other larger and more complex *N*-nitrosamines. Larger and varied substituents not only affect the efficiency of the α -carbon hydroxylation mechanism but can result in different detoxification mechanisms and ADME properties (such as solubility) affecting exposure levels and times, varying target organs, and involving different metabolism enzymes. Different competing mechanisms for mutagenicity can occur due to differences in structure and small structural variations can lead to significant differences in resulting potency. This makes the risk assessment of *N*-nitrosamines both complex and dependent on many variables, and significantly different than assessments of NDMA and NDEA.

4.2 Applying mechanistic analogs to support read-across of *N*-nitrosamines

This investigation has shown that structural features of the test article can be assessed to determine the nature of its metabolic activation (e.g., α -carbon hydroxylation) and if any chemical attributes may reduce or eliminate its carcinogenicity. These chemical attributes may be structural feature patterns encoded as structural alerts which can help in automatically performing this assessment. Once the dominant reaction mechanism of the test article has been identified along with any mitigation, a mechanistically appropriate set of reference compounds can be selected (i.e., based on mechanistic similarity) from a database of experimental data for comparison in a read-across exercise. Although the mechanistic analogs may not be as similar as some other structures (based on global structural similarity), their relevance to the reaction mechanism of the test article makes them a better choice for a read-across exercise in agreement with Read-Across Assessment

Framework (RAAF) [58], where structural similarity considerations are combined with elements from the mechanistic similarity and metabolic similarity.

In some cases, the presence of multiple structural features on the test article could affect the nature and rate of metabolic activation. In this case the feature that will more significantly change the potency should be selected and those analogs with that feature used for comparison.

Figure 12 shows a potential example of this read-across exercise. *N*-nitrosohydroxyl proline contains two different features that affect α -carbon hydroxylation: a carboxylic acid group substituted at the 2-position on the ring, partially blocking one α -carbon. There is also a hydroxyl group substituted at the 4-position on the ring. While the presence of the alcohol may reduce the potency of the test article with respect to nitrosopyrrolidine (TD_{50} of $0.679 \text{ mg kg}^{-1} \text{ day}^{-1}$) [26,27], the presence of the carboxylic acid group partially blocking metabolism at the α -carbon site is much more significant.

This observation is confirmed when looking at two analogs, both quite structurally similar to the test article and each containing one of these structural features. Analog 1 (*N*-nitroso-3-hydroxypyrrolidine) has a hydroxyl group in the same position as the test article, while analog 2 (*N*-nitroso-L-proline) has a carboxylic acid group in the same position. Whereas analog 1 had a relatively high TD_{50} value of $7.65 \text{ mg kg}^{-1} \text{ day}^{-1}$, analog 2 is non-carcinogenic altogether displaying the more significant effect. In this example, analog 2 would make a better choice for assessing the potency of *N*-nitrosohydroxyl proline in a read-across exercise since a typical assessment of a nitrosamine must start with the assumption of extreme potency (as defined in the cohort-of-concern) and then add in the effects of deactivating features. It is important to note that in this case, the presence of the acid group on the test article and analog 2 may have significant impact beyond any steric or electronic effects. This is because the acid group substantially impacts the ADME of these molecules, potentially in the following ways: Firstly, the acid group, negatively charged at physiological pH, increases the polarity (and consequentially solubility and potential for glucuronidation) and decreases the potential for cell membrane penetration, reducing both the need and potential for metabolism and thus the risk for metabolic activation. Secondly, should metabolic activation of acid-containing compounds occur (not all are negative[59], though many are[29]), it is likely to be via Cyp 2C9, which has the specific steric requirements[16,17] mentioned in section 1.1 that may prevent α -hydroxylation. These factors further reinforce the choice of analog 2 as the most suitable and the conclusion that potency is low or negligible.

Another potential use of SAR is in the creation of categorical mechanistic alerts to support a read-across exercise. Here a mechanistic alert represents a set of analogs with a similar potency and mechanism of action. Alerts matching the test article are first reviewed for mechanistic relevancy. A TD_{50} value representing the most appropriate alert may then be selected. In figure 13 we see an example where two alerts are defined representing two different sets of compounds with two different potency ranges. Here alert 2, with compounds of low potency (e.g., $TD_{50} > 15 \text{ mg kg}^{-1} \text{ day}^{-1}$), is selected as the more appropriate alert over alert 1 (medium potency, e.g., $TD_{50} 1.5\text{--}15 \text{ mg kg}^{-1} \text{ day}^{-1}$). As an alternative, the

structures in the matching alert group could be inspected for the potency value of the most similar analog in that group, which would result in the use of nitrosoproline as an analog, similar to the first approach.

5. Conclusions

This investigation into the structure-activity relationships responsible for differences in the relative carcinogenic potency (as defined using rodent TD₅₀ values) of dialkyl *N*-nitrosamines examined in detail the structural effects on the main driver of high-potency nitrosamines, namely α -carbon hydroxylation via metabolic activation. While there are many different features affecting nitrosamine carcinogenic potency, this investigation examined some of the electronic and steric effects responsible for lower carcinogenic potency and even non-carcinogenic nitrosamines.

Both electronic and steric effects can partially or totally inhibit a metabolism mechanism, potentially resulting in an alternative dominant metabolism mechanism, and/or a significant reduction or elimination of carcinogenic potency. We have shown (using both Ames study data and rodent carcinogenicity data) that increasing the number of α -carbon substitutions decreases the potency and positivity of nitrosamines, with potency decreasing as the number of α -carbon hydrogens is reduced due to additional substitutions. Substitutions on both sides of that nitrosamine's amine nitrogen continue this trend. It is not necessary for complete substitution (e.g., removal of all α -carbon hydrogens) to completely negate carcinogenicity nor it is necessary to have substitution on both sides of the amine.

Steric hindrance from bulky chemical groups attached directly to the amine nitrogen or to the α -carbon can both reduce or eliminate carcinogenicity. Again, it is not necessary to have steric hindrance on both sides of the amine to inhibit metabolic activation. While increasing chain length substitution, ring-size, and molecular weight can decrease carcinogenicity potency compared to very small (methyl, and ethyl substituted) nitrosamines, the nature of functional group attachments plays a more important role in the relative potency of larger nitrosamines.

Compounds containing strong electron-withdrawing groups at the β -carbon exhibit a large decrease in carcinogenicity and an increase in the prevalence of negative mutagenic compounds. Two, strong β electron-withdrawing groups exhibit an even more pronounced effect, while weak β electron-withdrawing groups exhibit little effects on potency though two weak groups show some limited effects.

This investigation identified several structural features that affect the potency of dialkyl *N*-nitrosamines by reducing or eliminating their metabolism. Consequently, when analogs are selected for a read-across to determine nitrosamine potency, their selections must be initially based upon assessment of the mechanistic domain and thus on the mechanistic similarity between the test article and potential analogs. Additionally, structural features affecting the metabolism of the test article must then be considered, either as explicit examples on the analog or as a functional group containing the same characteristics for modifying the metabolism of the test article, including those investigated here: the presence of α -

carbon substitution and strong β -electron-withdrawing groups. Consequently, performing a read-across exercise for a test article using NMDA or NDEA as analogs may not always be appropriate, especially for test articles of significantly different size and shape, or those with significant chemical functional groups.

This investigation is on-going, and the current results represent only a few of the categories in the nitrosamine SAR affecting their carcinogenicity potency. Future work will continue the investigation to elucidate the effects of additional categories on carcinogenicity potency.

Acknowledgements

The authors wish to acknowledge the members of the nitrosamine working group mentioned for their time and insight which have enabled us to perform the work described. Instem research reported in this publication was supported by the National Institute of Environmental Health Sciences of the National Institutes of Health under Award Number R44ES026909. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health

Abbreviations

AI	acceptable intake
ADME	absorption, distribution, metabolism, and elimination
CPDB	Carcinogenicity Potency Database
COC	cohort of concern
EMA	European Medicines Agency
EWG	electron-withdrawing group
FDA	U.S. Food and Drug Administration
LCDB	Lhasa Carcinogenicity Database
NDEA	<i>N</i> -nitrosodiethylamine
NDIPA	<i>N</i> -nitrosodiisopropylamine
NDMA	<i>N</i> -nitrosodimethylamine
NDSBA	<i>N</i> -nitrosodisecbutylamine
NMEA	<i>N</i> -nitrosomethylethylamine
NMNA	<i>N</i> -nitrosomethylneopentylamine
NMIPA	<i>N</i> -nitrosomethylisopropylamine
NMTBA	<i>N</i> -nitrosomethylterbutylamine
NPDA	<i>N</i> -nitrosodiphenylamine
SAR	structure activity relationship

TD₅₀ dose that results in a 50% excess tumor incidence

References

- [1]. European Medicines Agency (EMA), Temporary interim limits for NMBA, DIPNA, EIPNA, impurities in sartan blood pressure medicines. EMA/351053/2019 rev 1., 2019.
- [2]. Kroes R, Renwick AG, Cheeseman MA, Kleiner J, Mangelsdorf I, Piersma A, Schilter B, Schlatter J, Van Schothorst F, Vos JG, Würtzen G, Structure-based thresholds of toxicological concern (TTC): Guidance for application to substances present at low levels in the diet, *Food Chem. Toxicol* 42 (2004) 65–83. 10.1016/j.fct.2003.08.006. [PubMed: 14630131]
- [3]. SwissMedic, Potential nitrosamine contamination, (n.d.). <https://www.swissmedic.ch/swissmedic/en/home/news/mitteilungen/aufforderung-zlinhaberinnen-ham.html> (accessed June 22, 2021).
- [4]. European Medicines Agency (EMA), Procedure under Article 5(3) of Regulation EC (No) 726/2004: Nitrosamine impurities in human medicinal products. Procedure number: EMEA/H/A-5(3)/1490. EMA/369136/2020, (2020).
- [5]. European Medicines Agency (EMA), Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products. EMA/409815/2020, 2020.
- [6]. United States Food and Drug Administration (U.S. FDA), Control of Nitrosamine Impurities in Human Drugs, Guidance for Industry, 2021.
- [7]. Thresher A, Foster RS, Ponting DJ, Stalford SA, Tennant RE, Thomas R, Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data, *Regul. Toxicol. Pharmacol* 116 (2020) 104749. 10.1016/j.yrtph.2020.104749. [PubMed: 32777431]
- [8]. Thomas R, Thresher A, Ponting DJ, Utilisation of parametric methods to improve percentile-based estimates for the carcinogenic potency of nitrosamines, *Regul. Toxicol. Pharmacol* 121 (2021) 104875. 10.1016/j.yrtph.2021.104875. [PubMed: 33556416]
- [9]. Lijinsky W, Structure-activity relations in carcinogenesis by N-nitroso compounds, *Cancer Metastasis Rev.* 6 (1987) 301–356. 10.1007/BF00144269. [PubMed: 3319273]
- [10]. Guttenplan JB, N-nitrosamines: bacterial mutagenesis and in vitro metabolism, *Mutat. Res. -Rev. Genet. Toxicol* 186 (1987) 81–134. 10.1016/0165-1110(87)90026-1.
- [11]. Camus A-M, Geneste O, Honkakoski P, Béréziat J-C, Henderson CJ, Wolf RC, Bartsch H, Lang MA, High variability of nitrosamine metabolism among individuals: Role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans, *Mol. Carcinog* 7 (1993) 268–275. 10.1002/mc.2940070410. [PubMed: 8352885]
- [12]. Yamazaki H, Inui Y, Yun C-H, Guengerich FP, Shimada T, Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes, *Carcinogenesis*. 13 (1992) 1789–1794. 10.1093/carcin/13.10.1789. [PubMed: 1423839]
- [13]. Chowdhury G, Calcutt MW, Nagy LD, Guengerich FP, Oxidation of Methyl and Ethyl Nitrosamines by Cytochromes P450 2E1 and 2B1, *Biochemistry*. 51 (2012) 9995–10007. 10.1021/bi301092c. [PubMed: 23186213]
- [14]. Chowdhury G, Calcutt MW, Guengerich FP, Oxidation of N-nitrosoalkylamines by human cytochrome p450 2a6: Sequential oxidation to aldehydes and carboxylic acids and analysis of reaction steps, *J. Biol. Chem* 285 (2010) 8031–8044. 10.1074/jbc.M109.088039. [PubMed: 20061389]
- [15]. Hecht SS, Young R, Metabolic α -Hydroxylation of N-Nitrosomorpholine and 3,3,5,5-Tetrahydro-N-nitrosomorpholine in the F344 Rat, *Cancer Res.* 41 (1981) 5039–5043. [PubMed: 7307006]
- [16]. Lonsdale R, Houghton KT, Zurek J, Bathelt CM, Foloppe N, De Groot MJ, Harvey JN, Mulholland AJ, Quantum mechanics/molecular mechanics modeling of regioselectivity of drug metabolism in cytochrome P450 2C9, *J. Am. Chem. Soc* 135 (2013) 8001–8015. 10.1021/ja402016p. [PubMed: 23641937]

- [17]. Lewis DF, Ito Y, Human CYPs involved in drug metabolism: Structures, substrates and binding affinities, *Expert Opin. Drug Metab. Toxicol* 6 (2010) 661–674. 10.1517/17425251003674380. [PubMed: 20402561]
- [18]. Druckrey H, Preussmann R, Ivankovic S, Schmähl D, Afkham J, Blum G, Mennel HD, Müller M, Petropoulos P, Schneider H, Organotrope carcinogene Wirkungen bei 65 verschiedenen N-Nitroso-Verbindungen an BD-Ratten, *Z. Krebsforsch* 69 (1967) 103–201. 10.1007/BF00524152. [PubMed: 4230610]
- [19]. Carlson ES, *Metabolic Activation and DNA-Damaging Properties of Carcinogenic N-Nitrosamines*, University of Minnesota, 2019.
- [20]. Streeter AJ, Nims RW, Sheffels PR, Heur YH, Keefer LK, Yang CS, Mico BA, Gombar CT, Metabolic Denitrosation of N-Nitrosodimethylamine in Vivo in the Rat, *Cancer Res.* 50 (1990) 1144–1150. <https://pubmed.ncbi.nlm.nih.gov/2297762/> (accessed June 24, 2021). [PubMed: 2297762]
- [21]. Lijinsky W, Reuber MD, Transnitrosation by nitrosamines in vivo., *IARC Sci. Publ* (1982) 625–631. [PubMed: 7141570]
- [22]. Ji L, Schüürmann G, Computational evidence for α -nitrosamino radical as initial metabolite for both the P450 dealkylation and denitrosation of carcinogenic nitrosamines, *J. Phys. Chem. B* 116 (2012) 903–912. 10.1021/jp206570n. [PubMed: 22136655]
- [23]. Lhasa Limited, Vitic, (n.d.). <https://www.lhasalimited.org/products/vitic.htm> (accessed December 16, 2020).
- [24]. Instem, <https://www.instem.com/solutions/insilico/computational-toxicology.php>, (n.d.).
- [25]. Gold LS, Sawyer CB, Magaw R, Backman GM, De Veciana M, Levinson R, Hooper NK, Havender WR, Bernstein L, Pike MC, Ames BN, A carcinogenic potency database of the standardized results of animal bioassays, *Environ. Health Perspect VOL.* 58 (1984) 9–319. 10.2307/3429857. [PubMed: 6525996]
- [26]. Gold LS, Slone TH, Manley NB, Garfinkel GB, Hudes ES, Rohrbach L, Ames BN, The Carcinogenic Potency Database: analyses of 4000 chronic animal cancer experiments published in the general literature and by the U.S. National Cancer Institute/National Toxicology Program., *Environ. Health Perspect* 96 (1991) 11–15. 10.1289/ehp.919611. [PubMed: 1820251]
- [27]. Peto R, Pike MC, Bernstein L, Gold LS, Ames BN, The TD50: A proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments, *Environ. Health Perspect VOL.* 58 (1984) 1–8. 10.2307/3429856. [PubMed: 6525991]
- [28]. Thresher A, Gosling JP, Williams RV, Generation of TD50 values for carcinogenicity study data, *Toxicol. Res. (Camb)* 8 (2019) 696–703. 10.1039/c9tx00118b. [PubMed: 31588346]
- [29]. Tennant RE, Ponting DJ, Do all nitrosamines pose a significant level of genotoxic risk?, 2020. (n.d.). <https://www.lhasalimited.org/publications/do-all-nitrosamines-pose-a-significant-level-of-genotoxic-risk-webinar-presentation-slides/7748> (accessed June 17, 2021).
- [30]. Remya GS, Suresh CH, Quantification and classification of substituent effects in organic chemistry: A theoretical molecular electrostatic potential study, *Phys. Chem. Chem. Phys* 18 (2016) 20615–20626. 10.1039/c6cp02936a. [PubMed: 27412764]
- [31]. Weininger DM, SMARTS Theory Manual, Daylight Chemical Information Systems, Santa Fe, New Mexico, n.d.
- [32]. Jenkins GJS, Doak SH, Johnson GE, Quick E, Waters EM, Parry JM, Do dose response thresholds exist for genotoxic alkylating agents?, *Mutagenesis.* 20 (2005) 389–398. 10.1093/mutage/gei054. [PubMed: 16135536]
- [33]. Magee PN, Lee KY, Cellular injury and carcinogenesis. Alkylation of ribonucleic acid of rat liver by diethylnitrosamine and n-butylmethylnitrosamine in vivo., *Biochem. J* 91 (1964) 35–42. 10.1042/bj0910035. [PubMed: 5833387]
- [34]. Preussmann R, Habs M, Pool BL, Carcinogenicity and mutagenicity testing of three isomeric N-nitroso-N-methylaminopyridines in rats 2, *J. Natl. Cancer Inst* 62 (1979) 153–156. 10.1093/jnci/62.1.153. [PubMed: 364151]

- [35]. Greenblatt M, Lijinsky W, Failure to induce tumors in swiss mice after concurrent administration of amino acids and sodium nitrite, *J. Natl. Cancer Inst* 48 (1972) 1389–1392. 10.1093/jnci/48.5.1389. [PubMed: 5030954]
- [36]. Chu C, Magee PN, Metabolic Fate of Nitrosoproline in the Rat, *Cancer Res.* 41 (1981) 3653–3657. <https://pubmed.ncbi.nlm.nih.gov/6167353/> (accessed June 24, 2021). [PubMed: 6167353]
- [37]. Preussmann R, Stewart BW, N-nitroso carcinogens, in: Searle CE (Ed.), *Chem. Carcinog*, 2nd Ed., American Chemical Society (ACS), Washington D.C., 1984: pp. 643–828.
- [38]. Magee PN, Barnes JM, The production of malignant primary hepatic tumours in the rat by feeding dimethylnitrosamine, *Br. J. Cancer* 10 (1956) 114–122. 10.1038/bjc.1956.15. [PubMed: 13342328]
- [39]. Johnson GE, Dobo K, Gollapudi B, Harvey J, Kenny J, Kenyon M, Lynch A, Minocherhomji S, Nicolette J, Thybaud V, Wheeldon R, Zeller A, Permitted daily exposure limits for noteworthy N-nitrosamines, *Environ. Mol. Mutagen* 62 (2021) 293–305. 10.1002/em.22446. [PubMed: 34089278]
- [40]. Pottenger LH, Boysen G, Brown K, Cadet J, Fuchs RP, Johnson GE, Swenberg JA, Understanding the importance of low-molecular weight (ethylene oxide- and propylene oxide-induced) DNA adducts and mutations in risk assessment: Insights from 15 years of research and collaborative discussions, *Environ. Mol. Mutagen* 60 (2019) 100–121. 10.1002/em.22248. [PubMed: 30536466]
- [41]. Beard JC, Swager TM, An Organic Chemist's Guide to N-Nitrosamines: Their Structure, Reactivity, and Role as Contaminants, *J. Org. Chem* 86 (2021) 2037–2057. 10.1021/acs.joc.0c02774. [PubMed: 33474939]
- [42]. Phillipson CE, Ioannides C, A comparative study of the bioactivation of nitrosamines to mutagens by various animal species including man, *Carcinogenesis.* 5 (1984) 1091–1094. 10.1093/carcin/5.8.1091. [PubMed: 6744515]
- [43]. Scherer E, Timmer AP, Emmelot P, Formation by diethylnitrosamine and persistence of O4-ethylthymidine in rat liver DNA in vivo, *Cancer Lett.* 10 (1980) 1–6. 10.1016/0304-3835(80)90058-0. [PubMed: 7226125]
- [44]. Wani AA, Wani G, Ambrosio SMD, A human dna repair activity specific for o-ethylthymine: Identification and partial characterization, *Carcinogenesis.* 11 (1990) 1419–1424. 10.1093/carcin/11.8.1419. [PubMed: 2387029]
- [45]. Ding X, Kaminsky LS, Human Extrahepatic Cytochromes P450: Function in Xenobiotic Metabolism and Tissue-Selective Chemical Toxicity in the Respiratory and Gastrointestinal Tracts, *Annu. Rev. Pharmacol. Toxicol* 43 (2003) 149–173. 10.1146/annurev.pharmtox.43.100901.140251. [PubMed: 12171978]
- [46]. Lijinsky W, Joseph E, Melvin D, Sandra S, Esophageal carcinogenesis in f344 rats by nitrosomethylethylamines substituted in the ethyl group, *J. Natl. Cancer Inst* 68 (1982) 681–684. 10.1093/jnci/68.4.681. [PubMed: 6951082]
- [47]. Hecht SS, Approaches to Cancer Prevention Based on an Understanding of N-Nitrosamine Carcinogenesis, *Exp. Biol. Med* 216 (1997) 181–191. 10.3181/00379727-216-44168.
- [48]. Mochizuki M, Anjo T, Okada M, Isolation and characterization of N-alkyl-N-(hydroxymethyl)nitrosamines from N-alkyl-N-(hydroperoxymethyl)nitrosamines by deoxygenation, *Tetrahedron Lett.* 21 (1980) 3693–3696. 10.1016/S0040-4039(00)78747-8.
- [49]. Hecht SS, N-nitroso-2-hydroxymorpholine, a mutagenic metabolite of n-nitrosodiethanolamine, *Carcinogenesis.* 5 (1984) 1745–1747. 10.1093/carcin/5.12.1745. [PubMed: 6499128]
- [50]. Jancova P, Anzenbacher P, Anzenbacherova E, Phase II drug metabolizing enzymes, *Biomed. Pap* 154 (2010) 103–116. 10.5507/bp.2010.017.
- [51]. Michejda CJ, Koepke SR, Kroeger-Koepke MB, Bosan W, Recent findings on the metabolism of beta-hydroxyalkylnitrosamines., *IARC Sci. Publ* (1987) 77–82. <https://pubmed.ncbi.nlm.nih.gov/3316003/> (accessed June 30, 2021). [PubMed: 3316003]
- [52]. Keefer LK, Anjo T, Heur YH, Yang CS, Mico BA, Potential for metabolic deactivation of carcinogenic N-nitrosodimethylamine in vivo., *IARC Sci. Publ* (1987) 113–116. [PubMed: 3679346]

- [53]. Okada M, Suzuki E, Mochizuki M, Possible important role of urinary N methyl N (3 carboxypropyl)nitrosamine in the induction of bladder tumors in rats by N methyl N dodecyl nitrosamine, Gann, Japanese J. Cancer Res 67 (1976) 771–772. 10.20772/cancersci1959.67.5_771.
- [54]. Suzuki E, Mochizuki M, Okada M, Metabolic fate of N-methyl-N-dodecyl nitrosamine in the rat, in relation to its carcinogenicity to the urinary bladder, Gann, Japanese J. Cancer Res 72 (1981) 713–716.
- [55]. Peterson LA, Formation, repair, and genotoxic properties of bulky DNA adducts formed from tobacco-specific nitrosamines, J. Nucleic Acids 2010 (2010). 10.4061/2010/284935.
- [56]. Lee M, Ishizaki H, Brady JF, Yang CS, Substrate Specificity and Alkyl Group Selectivity in the Metabolism of N-Nitrosodialkylamines, Cancer Res. 49 (1989) 1470–1474. <https://pubmed.ncbi.nlm.nih.gov/2924300/> (accessed June 30, 2021). [PubMed: 2924300]
- [57]. Bellec G, Dréano Y, Lozach P, Ménez JF, Berthou F, Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes, Carcinogenesis. 17 (1996) 2029–2034. 10.1093/carcin/17.9.2029. [PubMed: 8824531]
- [58]. European Chemicals Agency (ECHA), Read-Across Assessment Framework (RAAF), 2017. 10.2823/619212.
- [59]. Hasegawa R, Futakuchi M, Mizoguchi Y, Yamaguchi T, Shirai T, Ito N, Lijinsky W, Studies of initiation and promotion of carcinogenesis by N-nitroso compounds, Cancer Lett. 123 (1998) 185–191. 10.1016/S0304-3835(97)00417-5. [PubMed: 9489487]

Research Highlights

- N-Nitrosamine carcinogenic potency ranges from extreme to negligible or negative
- Specific structural features have clear effects on N-nitrosamine carcinogenic potency
- Analysis of N-nitrosamine SAR may require investigation of potentials for metabolism, DNA binding and DNA repair
- Presence or absence of structural features can support read-across for novel *N*-nitrosamines




Figure 1.
 α -carbon hydroxylation of dialkyl *N*-nitrosamines











Figure 2:
Definitions of nitros(o)amide, nitroso-urea and similar compounds.



Et/Me only




Has Et/Me

CH₂ except Et/MeNo α-CH₂

R₁ = Ethyl or methyl
 R₂ = C except C=O or C=N
 R₃ = Any non-hydrogen atom

Figure 3:
 Visualisations of substructure patterns considered for identification of the degree of α-carbon branching



$R_1 = \text{C}$ except $\text{C}=\text{O}$ or $\text{C}=\text{N}$
 $R_2 = \text{O}, \text{N}, \text{S}$
 $R_3 = \text{H}, \text{C}, \text{F}, \text{Cl}, \text{Br}, \text{I}, \text{OC}, \text{NH}_2, \text{NHC}, \text{NC}_2$
 $R_4 = \text{F}, \text{Cl}, \text{Br}, \text{I}$
 $R_5 = \text{C}$ (aromatic)
 Bonds marked * may be double or triple
 Alpha carbon may be CH_2 or $\text{CH}(\text{C})$

Figure 4: Definitions of electron-withdrawing group patterns categorised by strength (as defined by strength of the withdrawing group[30]).




Figure 5.
Categorizing nitrosamine carcinogenicity TD₅₀ potency by structural features




Figure 6.
The effects of size and α -carbon substitution on nitrosamine potency







Figure 7. The effects of α -carbon substitution on nitrosamine carcinogenicity (208 compounds) and mutagenicity (281 compounds) prevalence




NDEA (positive)
2 open (CH₂) sites




NMIPA (positive)
1 hindered (iPr),
1 open (CH₂) site




NMTBA (negative)
1 blocked (tBu),
1 open (CH₂) site




NDIPA (weak positive)
2 hindered (iPr) sites




NMNA (positive)
2 open (CH₂) sites




2-(nitrosomethylamino)
pyridine (positive)
1 blocked (aryl),
1 open (CH₂) site




3-(nitrosomethylamino)
pyridine (negative)
1 blocked (aryl),
1 open (CH₂) site




NDSBA (negative)
2 hindered (iPr) sites



NDPA (very weak positive)
2 blocked (aryl) sites



2,6-dimethyl-N,N'-dinitroso
piperazine (positive)
L: 2 open (CH₂) sites,
R: 2 hindered (iPr) sites



methyl 1-methyl-6-nitro-2-nitroso-
1,3,4,9-tetrahydropyrido(3,4)-
indole-3-carboxylate (positive)
2 hindered (iPr) sites
aromatic nitro alerting feature

Figure 8.

Various *N*-nitrosamine structures with different substitution patterns and their rodent carcinogenicity calls




Figure 9. The effects of β -carbon electron withdrawing groups on nitrosamine carcinogenic potency





Figure 10. The effects of β -carbon electron withdrawing groups on nitrosamine carcinogenicity (208 compounds) and mutagenicity (281 compounds) prevalence



3F-NDEA (positive)
1 strong EWG

6F-NDEA (negative)
2 strong EWGs

nitroso-iminodiacetonitrile
(negative)
2 strong EWGs

nitroso-bis(2-oxopropylamine)
(positive) 2 weak EWGs

Figure 11.

Various *N*-nitrosamine structures with β -carbon electron withdrawing groups and their rodent carcinogenicity calls





Figure 12.
Assessing the most relevant mechanistic analog of an *N*-nitrosamine during a read-across exercise.

**Figure 13.**

Assessing the potency of an *N*-nitrosamine during a read-across exercise by first applying the most relevant mechanistic alert.